CrystalGenomics Inc (083790) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of CrystalGenomics Inc KRW 423, price KRW 930, upside -54.5%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range 744.00 KRW – 8,550 KRW · fair‑value band 242.67 KRW – 565.78 KRW · the 930.00 KRW price screens above the 422.74 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow CrystalGenomics in your weekly email
Every Wednesday you see whether CrystalGenomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial.
Show more
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Stock analysis
CrystalGenomics Inc (083790) currently trades at 930.00 KRW, while our model-based Fair Value estimate is 422.74 KRW, 54.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 916.22 KRW per share, and 0 of the 3 models we run sit above the 930.00 KRW price.
Bear case: the Dividend Discount group reads lowest at 362.64 KRW, and 3 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: 242.67 KRW (bear) to 565.78 KRW (bull), the price of 930.00 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
CrystalGenomics Inc reported revenue of 27.4B KRW in FY2025 versus 42.4B KRW in FY2021, a compound −10.3%/yr. Reported net income was −3.5B KRW in FY2025.
Key figures
Market cap 71.5B KRW (≈ $53.3M) · P/S ratio 1.59 · Dividend yield 3.5% · Net margin −12.9% · Return on equity −4,221% · Return on assets (EBIT) −10.8% · Operating margin −43.3% · Revenue (TTM) 45.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 43% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at −55%, 083790 screens richer than that median.
Fair Value models
Bear 242.67 KRWFair Value 422.74 KRWBull 565.78 KRW
Price 930.00 KRW · Upside -54.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+277.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic). Over 10 years: +16.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
26.2% (2020) → −95.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 42 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside−54.5% · Bottom 25%
Profitability
Return on assets−3.8% · Bottom 25%
Net margin (TTM)−64.6% · Bottom 25%
Operating margin (TTM)−43.3% · Bottom 25%
Growth and dividend
Revenue growth−0.8% · Bottom 25%
Dividend yield (TTM)3.5% · Top 25%
Balance sheet
Debt / equity0.40× · Highest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)0· sector 60
PAST (return on equity)0· sector 19
HEALTH (low debt)80· sector 98
DIVIDEND (yield)70· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "CrystalGenomics Inc Fair Value". https://www.fairvalue-calculator.com/stock/083790
Frequently asked questions
Is CrystalGenomics Inc (083790) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 422.74 KRW versus a price of 930.00 KRW, about −55% upside (overvalued).
What is the fair value of 083790?
Our model-based fair value for CrystalGenomics Inc is 422.74 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 930.00 KRW.
What is the quality score of 083790?
CrystalGenomics Inc has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CrystalGenomics Inc (083790)?
Our model-based price target is the fair value of 422.74 KRW (as of Oct 2, 2026) from 3 valuation models. Cautious scenario 242.67 KRW, optimistic scenario 565.78 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CrystalGenomics Inc stock forecast for 2026?
Our models put fair value at 422.74 KRW, about −55% upside versus a price of 930.00 KRW (overvalued). Cautious scenario 242.67 KRW, optimistic scenario 565.78 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CrystalGenomics Inc (083790)?
CrystalGenomics Inc reported trailing-twelve-month revenue of about 45.0B KRW (latest available figure, as of Oct 2, 2026).
Does CrystalGenomics Inc pay a dividend?
CrystalGenomics Inc currently shows a dividend yield of about 3.52% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of CrystalGenomics Inc (083790)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CrystalGenomics Inc it is 422.74 KRW per share (as of Oct 2, 2026), against a price of 930.00 KRW. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is CrystalGenomics Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 083790 trades above its calculated fair value: price 930.00 KRW, fair value 422.74 KRW, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 083790?
No. The price is what the market pays today (930.00 KRW); the fair value is what the company's own numbers justify (422.74 KRW). For CrystalGenomics Inc the two are 507.26 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CrystalGenomics Inc worth?
The market values CrystalGenomics Inc at about 71.5B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 930.00 KRW; our models calculate a fair value of 422.74 KRW per share.
What do the bullish and bearish scenarios say about 083790?
Our models span a range for CrystalGenomics Inc: cautious scenario 242.67 KRW, base 422.74 KRW, optimistic 565.78 KRW per share (as of Oct 2, 2026, price 930.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CrystalGenomics Inc (083790)?
Balance-sheet figures for CrystalGenomics Inc (as of Oct 2, 2026): debt of 0.40 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 083790 from its 52-week high?
CrystalGenomics Inc trades at 930.00 KRW, about 43% below its 52-week high of 1,637 KRW and 25% above the low of 744.00 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 422.74 KRW is for.
Which stocks are comparable to CrystalGenomics Inc?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CrystalGenomics Inc stock attractive at the current price?
The data as of Oct 2, 2026: price 930.00 KRW, calculated fair value 422.74 KRW (−55%), Quality Score 44/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 083790 calculated?
We run CrystalGenomics Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 422.74 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CrystalGenomics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CrystalGenomics Inc (083790)?
The closing price on Oct 2, 2026 was 930.00 KRW. Our model-based fair value is 422.74 KRW, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CrystalGenomics Inc right now?
The price sits above even our optimistic bull case (565.78 KRW). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (242.67 KRW to 565.78 KRW) leaves room in how you read the outcome.
Key figures of CrystalGenomics Inc
How large is the market capitalisation of CrystalGenomics Inc (083790)?
The market capitalisation of CrystalGenomics Inc is 71.5B KRW (≈ $53.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CrystalGenomics Inc (083790)?
The price-to-sales ratio of CrystalGenomics Inc is 1.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of CrystalGenomics Inc (083790)?
The dividend yield of CrystalGenomics Inc is 3.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CrystalGenomics Inc (083790)?
The net margin of CrystalGenomics Inc is −12.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CrystalGenomics Inc (083790)?
The return on equity (ROE) of CrystalGenomics Inc is −4,221% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CrystalGenomics Inc (083790)?
On an EBIT basis the return on assets of CrystalGenomics Inc is −10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CrystalGenomics Inc (083790)?
The operating margin of CrystalGenomics Inc is −43.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CrystalGenomics Inc (083790)?
Revenue at CrystalGenomics Inc is growing −0.8% versus a year earlier (3y avg +85.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CrystalGenomics Inc (083790) generate?
The free cash flow of CrystalGenomics Inc is −25.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CrystalGenomics Inc (083790) carry?
The net debt of CrystalGenomics Inc is 32.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CrystalGenomics Inc in the live analysis
One click puts CrystalGenomics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
